Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association’s 2022 Annual Conference
09. März 2022 09:00 ET
|
Rockwell Medical, Inc.
WIXOM, Mich., March 09, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of...
Rockwell Medical, Inc. to Present at Aegis Virtual Conference
15. Februar 2022 08:30 ET
|
Rockwell Medical, Inc.
WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of...
Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14. Februar 2022 16:05 ET
|
Rockwell Medical, Inc.
WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...
Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea
20. Januar 2022 09:15 ET
|
Rockwell Medical, Inc.
WIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...
Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea
13. Januar 2022 08:21 ET
|
Rockwell Medical, Inc.
-Commercial launch expected in June/July 2022- -Rockwell Medical has an exclusive license agreement with Jeil Pharmaceutical Co., Ltd., for the rights to Triferic® and Triferic® AVNU in South Korea-...
Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2022 Conference
07. Januar 2022 12:00 ET
|
Rockwell Medical, Inc.
WIXOM, Mich., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of...
Rockwell Medical Receives Important Feedback from FDA on its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion
14. Dezember 2021 09:00 ET
|
Rockwell Medical, Inc.
WIXOM, Mich., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...
Rockwell Medical Study Demonstrates No Drug-drug Interaction Between Ferric Pyrophosphate Citrate and Unfractionated Heparin
16. November 2021 16:01 ET
|
Rockwell Medical, Inc.
WIXOM, Mich., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...
Rockwell Medical, Inc. Provides Third Quarter 2021 Financial and Operational Update
15. November 2021 16:00 ET
|
Rockwell Medical, Inc.
- Third quarter net sales of $16.0 Million, up 6% sequential quarter-over-quarter and 5% year-over-year - - Company recently submitted Investigational New Drug application with FDA for its...
Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12. November 2021 16:05 ET
|
Rockwell Medical, Inc.
WIXOM, Mich., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...